The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The cardiovascular health study

Journal of the American Geriatrics Society

Volumn 52, Issue 10, 2004, Pages 1639-1647

  Psaty, Bruce M ^a   Anderson, Melissa ^b   Kronmal, Richard A ^b   Tracy, Russell P ^c   Orchard, Trevor ^d   Fried, Linda P ^e   Lumley, Thomas ^b   Robbins, Johnx ^f   Burke, Greg ^g   Newman, Anne B ^d   Furberg, Curt D ^g  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cholesterol; Lipids; Myocardial infarction; Older adults; Stroke; Total mortality

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; LIPID;

ADULT; AFRICAN AMERICAN; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INCIDENCE; MALE; MORTALITY; POPULATION RESEARCH; PROSPECTIVE STUDY; STROKE; AGED; BLOOD; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; HEALTH SURVEY; METHODOLOGY; MULTICENTER STUDY; NEGRO; RISK FACTOR; UNITED STATES;

AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; CEREBROVASCULAR ACCIDENT; FEMALE; HEALTH SURVEYS; HUMANS; INCIDENCE; LIPIDS; MALE; MORTALITY; MYOCARDIAL INFARCTION; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 6944229737     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2004.52455.x     Document Type: Article

References (47)

1. Stamler J, Wentworth D, Neaton JD et al. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-2828.
2. Stamler J, Daviglus ML, Garside DB et al. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000;284: 311-318.
3. Manolio TA, Pearson TA, Wenger NK et al. Cholesterol and heart disease in older persons and women: review of NHLBI workshop. Ann Epidemiol 1992;2:161-176.
4. Benfante R, Reed D. Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly? JAMA 1990;263:393-396.
5. Castelli WP, Wilson WF, Levy D et al. Cardiovascular risk factors in the elderly. Am J Cardiol 1989;63(Suppl):12H-19H.
6. Corti MC, Guralnik JM, Salive ME et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA 1995;274:539-544.
7. Wilson PWF, D'Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.
8. Kronmal RA, Cain KC, Ye Z et al. Total serum cholesterol levels and mortality risk as a function of age. Arch Intern Med 1993;153:1065-1073.
9. Psaty BM, Koepsell TD, Manolio TA et al. Risk ratios and risk differences in estimating the effect of risk factors for cardiovascular disease in the elderly. J Clin Epidemiol 1990;43:961-970.
10. Iso H, Jacobs DR Jr, Wentworth D et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med 1989;320:904-910.
11. Sacco RL, Benson RT, Kargman DE et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly. JAMA 2001;285:2729-2735.
12. Schatz IJ, Masaki K, Yano K et al. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: A cohort study. Lancet 2001;358:351-355.
13. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM et al. Total cholesterol and risk of mortality in the oldest old. Lancet 1997;350:1119-1123.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
15. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
16. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
17. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with Simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
18. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-1622.
19. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled trial. Lancet 2002;360:1623-1630.
20. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.
21. Fried LP, Borhani NO, Enright P et al. The Cardiovascular Health Study: Design Rationale. Ann Epidemiol 1991;1:263-276.
22. Tell GS, Fried LP, Hermanson B et al. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol 1993;3:358-366.
23. Psaty BM, Kuller LH, Bild D et al. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. Ann Epidemiol 1995;5:270-277.
24. Psaty BM, Lee M, Savage PJ et al. Assessing the use of medications in the elderly: Method and initial results in the Cardiovascular Health Study. J Clin Epidemiol 1992;45:683-692.
25. Cushman M, Cornell ES, Howard PR et al. Laboratory methods and quality control in the Cardiovascular Health Study. Clin Chem 1995;41:264-270.
26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of preparative ultracentrifuge. Clin Chem 1972;18:499-501.
27. O'Leary DH, Polak JF, Wolfson SK Jr et al. The use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. Stroke 1991;22:1155-1163.
28. Ives DG, Fitzpatrick AL, Bild DE et al. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ann Epidemiol 1995;5:278-285.
29. Price TR, Psaty B, O'Leary D et al. Assessment of cerebrovascular disease in the Cardiovascular Health Study. Ann Epidemiol 1993;3:504-507.
30. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.
31. Psaty BM, Furberg CD, Kuller LH et al. The association between level of blood pressure and the risk of myocardial infarction, stroke and total mortality. The Cardiovascular Health Study. Arch Intern Med 2001;161:1183-1192.
32. Cox DR, Oakes D. Analysis of Survival Data. London: Chapman & Hall, 1984.
33. Ettinger WH, Wahl PW, Kuller LH et al. Lipoprotein lipids in older people: Results from the Cardiovascular Health Study. Circulation 1992;86:858-869.
34. Lemaitre RN, Furberg CD, Newman AB et al. Time trends in the use of cholesterol-lowering agents in older adults. The Cardiovascular Health Study. Arch Intern Med 1998;158:1761-1768.
35. Lemaitre RN, Psaty BM, Heckbert SR et al. Therapy with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: Evidence from the Cardiovascular Health Study. Arch Intern Med 2002;162:1395-1400.
36. Castelli WP, Anderson K, Wilson PW et al. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992;2:23-128.
37. Ettinger WH Jr, Harris T, Verdery RB et al. Evidence for inflammation as a cause of hypocholesterolemia in older people. J Am Geriatr Soc 1995;43: 264-266.
38. Vopato S, Leveille SG, Corti MC et al. The value of serum albumin and high-density lipoprotein cholesterol in defining mortality risk in older persons with low serum cholesterol. J Am Geriatr Soc 2001;49:1142-1149.
39. D'Agostino RB, Grundy S, Sullivan LM et al. Validation of the Framingham coronary heart disease prediction scores. JAMA 2001;286:180-187.
40. Alderman MH, Furberg CD, Kostis JB et al. Hypertension guidelines: Criteria that might make them more clinically useful. Am J Hypertens 2002;15: 917-923.
41. Hebert PR, Gaziano JM, Chan KS et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: An overview of randomized trials. JAMA 1997;278:313-321.
42. Fedder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: Projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 2002;105:152-156.
43. Psaty BM, Weiss NS, Furberg CD et al. Surrogate endpoints, health outcomes, and the drug approval process for the treatment of risk factors for cardiovascular disease. JAMA 1999;282:786-790.
44. Undas A, Brummel KE, Musial J et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001;103:2248-2253.
45. Albert MA, Danielson E, Rifai N et al. Effect of statin therapy on C-reactive protein levels. JAMA 2001;286:64-70.
46. Frenette PS. Locking a leukocyte integrin with statins. N Engl J Med 2001; 345:1419-1421.
47. Eto M, Kozai T, Cosentino F et al. Statin prevents tissue factor expression in human endothelial cells role of Rho/Rho-Kinase and Akt Pathways. Circulation 2002;105:1756-1759.